"The approval of HEMGENIX reflects groundbreaking science in delivering a medicine that we believe can transform the treatment options for both the people living with haemophilia B and the healthcare professionals who treat them,” said Dr Andrew Nash, senior vice president, head of research and chief scientific officer at CSL. …
Australian patients now one step closer to accessing CSL's one-time gene therapy
March 21, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product
August 13, 2026 - - Latest News -
Survey exposes deep gaps in neurological care across Australia
August 13, 2026 - - Latest News -
US childhood vaccine move away from combinations contrasts with Australia’s national schedule
August 12, 2026 - - Latest News -
Former minister joins DBG Health board as company broadens healthcare ambition
August 12, 2026 - - Latest News -
A sage appointment that puts DBG Health another step closer to a serious understanding of decision-making
August 12, 2026 - - Latest News -
Patients welcome the timely PBS listing of rare cancer therapy
August 12, 2026 - - Latest News -
How education exposes the moral and ethical limits of our health decision-making
August 11, 2026 - - Latest News